These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 11727933)

  • 21. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells.
    Huang Y; Ibrado AM; Reed JC; Bullock G; Ray S; Tang C; Bhalla K
    Leukemia; 1997 Feb; 11(2):253-7. PubMed ID: 9009089
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells.
    Anuchapreeda S; Leechanachai P; Smith MM; Ambudkar SV; Limtrakul PN
    Biochem Pharmacol; 2002 Aug; 64(4):573-82. PubMed ID: 12167476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of survivin on multidrug resistance mediated by P-glycoprotein in MCF-7 and its adriamycin resistant cells.
    Liu F; Xie ZH; Cai GP; Jiang YY
    Biol Pharm Bull; 2007 Dec; 30(12):2279-83. PubMed ID: 18057712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. P-glycoprotein as a drug target in the treatment of multidrug resistant cancer.
    Lehne G
    Curr Drug Targets; 2000 Jul; 1(1):85-99. PubMed ID: 11475537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug-stimulated ATPase activity of the human P-glycoprotein.
    Scarborough GA
    J Bioenerg Biomembr; 1995 Feb; 27(1):37-41. PubMed ID: 7629050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR).
    Teodori E; Dei S; Martelli C; Scapecchi S; Gualtieri F
    Curr Drug Targets; 2006 Jul; 7(7):893-909. PubMed ID: 16842220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. P-glycoprotein confers methotrexate resistance in 3T6 cells with deficient carrier-mediated methotrexate uptake.
    de Graaf D; Sharma RC; Mechetner EB; Schimke RT; Roninson IB
    Proc Natl Acad Sci U S A; 1996 Feb; 93(3):1238-42. PubMed ID: 8577747
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Purification and reconstitution of human P-glycoprotein.
    Ambudkar SV; Lelong IH; Zhang J; Cardarelli C
    Methods Enzymol; 1998; 292():492-504. PubMed ID: 9711577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. P-glycoprotein, multidrug resistance and tumor progression.
    Bradley G; Ling V
    Cancer Metastasis Rev; 1994 Jun; 13(2):223-33. PubMed ID: 7923552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-time monitoring of P-glycoprotein activation in living cells.
    Landwojtowicz E; Nervi P; Seelig A
    Biochemistry; 2002 Jun; 41(25):8050-7. PubMed ID: 12069596
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of H+-ATPase-dependent activity of multidrug resistance-associated protein in homoharringtonine-resistant human leukemic K562 cells.
    Benderra Z; Morjani H; Trussardi A; Manfait M
    Leukemia; 1998 Oct; 12(10):1539-44. PubMed ID: 9766497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Both Pgp and MRP1 activities using calcein-AM contribute to drug resistance in AML.
    Legrand O; Simonin G; Perrot JY; Zittoun R; Marie JP
    Adv Exp Med Biol; 1999; 457():161-75. PubMed ID: 10500791
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vinflunine (20',20'-difluoro-3',4'-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro.
    Etievant C; Barret JM; Kruczynski A; Perrin D; Hill BT
    Invest New Drugs; 1998; 16(1):3-17. PubMed ID: 9740539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence for functional discrimination between leukemic cells overexpressing multidrug-resistance associated protein and P-glycoprotein.
    Benderra Z; Morjani H; Trussardi A; Manfait M
    Adv Exp Med Biol; 1999; 457():151-60. PubMed ID: 10500790
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evidence for a constitutive, verapamil-sensitive, non-P-glycoprotein multidrug resistance phenotype in malignant glioma that is unaltered by radiochemotherapy in vivo.
    Rieger L; Rieger J; Winter S; Streffer J; Esser P; Dichgans J; Meyermann R; Weller M
    Acta Neuropathol; 2000 May; 99(5):555-62. PubMed ID: 10805101
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of the multidrug transporter P-glycoprotein is inversely related to that of apoptosis-associated endogenous TRAIL.
    Souza PS; Madigan JP; Gillet JP; Kapoor K; Ambudkar SV; Maia RC; Gottesman MM; Fung KL
    Exp Cell Res; 2015 Aug; 336(2):318-28. PubMed ID: 26101157
    [TBL] [Abstract][Full Text] [Related]  

  • 37. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications.
    Michieli M; Damiani D; Ermacora A; Masolini P; Raspadori D; Visani G; Scheper RJ; Baccarani M
    Br J Haematol; 1999 Feb; 104(2):328-35. PubMed ID: 10050716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in intra- or extracellular pH do not mediate P-glycoprotein-dependent multidrug resistance.
    Altenberg GA; Young G; Horton JK; Glass D; Belli JA; Reuss L
    Proc Natl Acad Sci U S A; 1993 Oct; 90(20):9735-8. PubMed ID: 8105483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel mechanisms of drug resistance in leukemia.
    Ross DD
    Leukemia; 2000 Mar; 14(3):467-73. PubMed ID: 10720143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters.
    Cardarelli CO; Aksentijevich I; Pastan I; Gottesman MM
    Cancer Res; 1995 Mar; 55(5):1086-91. PubMed ID: 7866993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.